In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, drug manufacturers, and pharmacies. This gives them a uniquely powerful ...

Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

It’s not only insulin. The FTC on Jan. 14 released a report charging PBMs with driving up prices for specialty drugs to treat cancer, HIV, and other illnesses. PBMs say they add value to the ...

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

Last year, the Federal Trade Commission (FTC) caused consternation among pharmacy benefit managers (PBMs) after it claimed the middlemen in the pharma supply chain were ramping up costs for patients.

condemnation of PBMs is one of the rare points where Trump can find common cause with progressive lawmakers like Elizabeth Warren and activist regulators at Joe Biden’s Federal Trade Commission ...